Delivery Order SPE2DB25D3018-SPE2DB25FUYFA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,718.44 to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 tablets. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The work will be...
- The Defense Logistics Agency awarded a $20,147.40 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 tablets. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $8,129.27 to AmerisourceBergen Drug Corp for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 units. The contract, issued on July 14, 2025, with completion targeted for July 15, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. This delivery order is a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,119.30 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100, 100 tablets, with an ultimate completion date of June 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order valued at $2,040.63 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 100s, a pharmaceutical product used for malaria prophylaxis and treatment. The contract, awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,217.11 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 (100 tablets), with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Atovaquone-Proguanil is an antimalarial medication commonly prescribed for malaria prophylaxis and treatment,...
- The Defense Logistics Agency awarded a $8,058.96 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Atovaquone-Proguanil 250-100mg in quantities of 100 units. The contract, which represents a non-set-aside competitive award, is scheduled for completion by August 25, 2025, with performance to be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $13,673.47 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100, a pharmaceutical product typically used for malaria prevention and treatment. The contract was awarded on September 16, 2025, with a completion date of September 17, 2025, and employs firm fixed-price pricing with no set-aside designation, indicating competitive award. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $22,386 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 units of Atovaquone-Proguanil 250-100, an antimalarial medication commonly used by military personnel for malaria prophylaxis. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award under the company's existing indefinite delivery contract with DLA. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) valued at $5,485.80 under a firm fixed-price contract. The award was issued on July 29, 2025, with an ultimate completion date of July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This is a non-set-aside award issued competitively, reflecting AmerisourceBergen's continued capability to meet federal...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUYFADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,504.61 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100 (100 count) on August 11, 2025, with completion scheduled for August 12, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills critical medical procurement needs for the Defense Health Agency and military healthcare systems. The Atovaquone-Proguanil antimalarial medication supports military personnel health protection, particularly for malaria prophylaxis in deployed and training environments. As a competitive award under the broader DLA pharmaceutical prime vendor framework, this delivery order demonstrates the contractor's ongoing capability to provide specialized pharmaceutical products across the federal medical supply chain. The award reflects the agency's continued reliance on AmerisourceBergen's extensive portfolio to meet diverse therapeutic and geographic healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 8/11/25 |